Vinícius Campos

Dr. Vinícius Campos

Universidade Federal Fluminense –UFF
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AJAlessandro K. Jordão
Alessandro K. Jordão
PSPlínio C. Sathler
Plínio C. Sathler
Vitor ferreiraVitor ferreira
Vitor ferreira
VCVinícius Campos
Vinícius Campos
MSMaria Cecília B.V. De Souza
Maria Cecília B.V. De Souza
ACAnna C. Cunha
Anna C. Cunha

1 August 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FDFlaviana R.F. Dias
Flaviana R.F. Dias
JNJuliana S. Novais
Juliana S. Novais
TDTalita A. Do Nascimento Santos Devillart
Talita A. Do Nascimento Santos Devillart
WSWanderson Amaral da Silva
Wanderson Amaral da Silva
MFMatheus O. Ferreira
Matheus O. Ferreira
ACAnna C. Cunha
Anna C. Cunha

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FSFlávia F. Silveira
Flávia F. Silveira
JSJuliana O. de Souza
Juliana O. de Souza
LHLucas V.B. Hoelz
Lucas V.B. Hoelz
VCVinícius Campos
Vinícius Campos
VJValquíria A.P. Jabor
Valquíria A.P. Jabor
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro

1 November 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
VCVinícius Campos
Vinícius Campos
PAPaula Abreu
Paula Abreu
HCHelena Carla Castro
Helena Carla Castro
CRCarlos R. Rodrigues
Carlos R. Rodrigues
AJAlessandro K. Jordão
Alessandro K. Jordão
ACAnna C. Cunha
Anna C. Cunha

27 March 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
JNJuliana S. Novais
Juliana S. Novais
VCVinícius Campos
Vinícius Campos
ASAna Carolina J. A. Silva
Ana Carolina J. A. Silva
MSMaria Cecília B.V. De Souza
Maria Cecília B.V. De Souza
Vitor ferreiraVitor ferreira
Vitor ferreira
ACAnna C. Cunha
Anna C. Cunha
Pathogenic bacteria may cause serious infections, such as pneumonia, which can be fatal especially to immunosuppressed individuals. Hospitalized patients are particularly susceptible to antibiotic-resistant infections, which are worsened when caused by resistant Gram-negative pathogens due to there being few therapeutic options available. Thus, this work describes the synthesis and in vitro antimicrobial profile of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates and their halogenated aminoquinones against Gram-positive and Gram-negative bacteria. Interestingly, these bioactive substances have shown promising activity against Gram-negative pathogenic strains. Among these derivatives, two non-halogenated amino compounds exhibited promising MIC and MBC values (MIC = MBC = 1–2 μg mL−1) against Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853, two Gram-negative strains of clinical importance. In addition, mono- and di-brominated aminoquinones were also effective in preventing the growth of E. coli (MIC = MBC = 2–4 μg mL−1). The in vitro hemocompatibility evaluation showed a low toxicity profile for the active aminoquinones in hemolysis assays. These results suggest that these substances have potential for exploring the design of new antimicrobial prototypes against Gram-negative bacteria.

25 September 2012 in RSC Advances
Verified
Journal Article
Closed access
PDF file
VCVinícius Campos
Vinícius Campos
ESEvelyne A. dos Santos
Evelyne A. dos Santos
Vitor ferreiraVitor ferreira
Vitor ferreira
RMRaquel C. Montenegro
Raquel C. Montenegro
MSMaria Cecília B.V. De Souza
Maria Cecília B.V. De Souza
ACAnna C. Cunha
Anna C. Cunha
A novel series of carbohydrate-based 1,2-naphthoquinones 13a–c and their substituted phenylhydrazono derivatives 14a–l were synthesized and evaluated for cytotoxicity against HL-60, MDA-MB435, HCT-116 and SF-295 cancer cell lines. The compounds 9a–c showed the best cytotoxicity profile (IC50 below 2 μM) against HL-60 and MDA-MB 435 human cells, while the hydrazone derivative 14i (IC50 HL-60 1.65 μM) was selective for leukemia when compared to the reference drug doxorubicin. None of the compounds exhibited lytic effects against mouse erythrocytes. Characterization of all compounds was confirmed by one- and two-dimensional NMR techniques (1H, 13C-APT, COSY-1H × 1H and HETCOR 1JCH) and by elemental analysis.